Zenodo: Extended data for ‘Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial’.https://doi.org/10.5281/zenodo.687433917. This evidence concerns the gene AR and prostate carcinoma.